Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Effects on Hepatic FFA Metabolism (C11 PET Study)
NCT01729156Phase 4Completed
- Start
- Jan 2013
- Primary completion
- May 2017
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of metformin in type 2 diabetes mellitus (T2DM) and dyslipidemia. Primary endpoint: Hepatic Fatty Acid Oxidation at 90 days. Started Jan 2013; status: completed.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT01729156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01729156.